| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Pulmonary and Critical Care Medicine, University of Miami School of Medicine at Mount Sinai Medical Center, Miami Beach, Florida 33140; and 2 Inspire Pharmaceutical, Inc., Durham, North Carolina 27703
The purpose of
this study was to determine whether aerosolized INS316 (UTP) stimulates
lung mucociliary clearance (MCC) in sheep and, if so, to compare its
effects with INS365, a novel P2Y2-receptor agonist. In the
first series of studies, we used a previously described
roentgenographic technique to measure tracheal mucus velocity (TMV), an
index of MCC, before and for 4 h after aerosolization of INS316
(10
1 M and
102 M) and INS365
(101 M and
102 M), or normal saline in
a randomized crossover fashion (n = 6). In a second series of studies, we compared the ability of these agents to enhance total lung clearance. For these tests, the clearance of inhaled technetium-labeled human serum albumin was measured serially
over a 2-h period after aerosolization of
101 M concentration of each
agent (n = 7). Aerosolization of both P2Y2-receptor agonists induced
significant dose-related increases in TMV
(P < 0.05) compared with saline. The
greatest increase in TMV was observed between 15 and 30 min after drug
treatment. The highest dose
(101 M) of INS316 produced
a greater overall stimulation of TMV than did INS365
(101 M). Both compounds,
compared with saline, induced a significant increase in MCC
(P < 0.05) within 20 min of
treatment. This enhancement in MCC began to plateau at 60 min. Although
the response to INS316 started earlier, there was no significant
difference between the clearance curves for the two compounds. We
conclude that inhaled P2Y2-receptor agonists can
increase lung MCC in sheep and that for
P2Y2-receptor stimulation TMV
accurately reflects changes in whole lung MCC.
tracheal mucus velocity; total lung clearance; pharmacology; airway receptors
This article has been cited by other articles:
|
|
 |
|
  N. S. Joo, J. J. Wine, and A. W. Cuthbert Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans Am J Physiol Lung Cell Mol Physiol, May 1, 2009; 296(5): L811 - L824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Rogers, W. M. Abraham, K. A. Brogden, J. F. Engelhardt, J. T. Fisher, P. B. McCray Jr., G. McLennan, D. K. Meyerholz, E. Namati, L. S. Ostedgaard, et al. The porcine lung as a potential model for cystic fibrosis Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L240 - L263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Scuri, J. R. Sabater, and W. M. Abraham Hyaluronan blocks porcine pancreatic elastase-induced mucociliary dysfunction in allergic sheep J Appl Physiol, June 1, 2007; 102(6): 2324 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Sabater, T. A. Lee, and W. M. Abraham Comparative Effects of Salmeterol, Albuterol, and Ipratropium on Normal and Impaired Mucociliary Function in Sheep Chest, November 1, 2005; 128(5): 3743 - 3749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Abraham, A. J. Bourdelais, J. R. Sabater, A. Ahmed, T. A. Lee, I. Serebriakov, and D. G. Baden Airway Responses to Aerosolized Brevetoxins in an Animal Model of Asthma Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 26 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Hirsh, J. R. Sabater, A. Zamurs, R. T. Smith, A. M. Paradiso, S. Hopkins, W. M. Abraham, and R. C. Boucher Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 929 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Blaug, J. Rymer, S. Jalickee, and S. S. Miller P2 purinoceptors regulate calcium-activated chloride and fluid transport in 31EG4 mammary epithelia Am J Physiol Cell Physiol, April 1, 2003; 284(4): C897 - C909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sabater, A. Wanner, and W. M. Abraham Montelukast Prevents Antigen-induced Mucociliary Dysfunction in Sheep Am. J. Respir. Crit. Care Med., December 1, 2002; 166(11): 1457 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Yerxa, J. R. Sabater, C. W. Davis, M. J. Stutts, M. Lang-Furr, M. Picher, A. C. Jones, M. Cowlen, R. Dougherty, J. Boyer, et al. Pharmacology of INS37217 [P1-(Uridine 5')-P4- (2'-deoxycytidine 5')tetraphosphate, Tetrasodium Salt], a Next-Generation P2Y2 Receptor Agonist for the Treatment of Cystic Fibrosis J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 871 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kellerman P2Y2 Receptor Agonists* : A New Class of Medication Targeted at Improved Mucociliary Clearance Chest, May 1, 2002; 121 (2009): 201S - 205S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. BENNETT, K. L. ZEMAN, C. FOY, C. L. SHAFFER, F. L. JOHNSON, J. A. REGNIS, A. SANNUTI, and J. JOHNSON Effect of Aerosolized Uridine 5'-Triphosphate on Mucociliary Clearance in Mild Chronic Bronchitis Am. J. Respir. Crit. Care Med., July 15, 2001; 164(2): 302 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Morse, J. L. Smullen, and C. W. Davis Differential effects of UTP, ATP, and adenosine on ciliary activity of human nasal epithelial cells Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1485 - C1497. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
